Articles
-
Comments to CMS on the Inflation Reduction Act’s Drug Price Negotiation Program
Over 20 researchers cosigned a comment letter to Centers for Medicaid and Medicare Services providing recommendations for the Medicare Drug Price Negotiation Program
Categorized in -
New Schaeffer White Paper Offers Solutions to Ensure Greater Patient Access to Prescription Drugs
The researchers propose three strategies for mitigating negative impacts of the Inflation Reduction Act to ensure greater patient access, increased innovation and lower costs.
Categorized in -
Senate Finance Committee Explores Costly, Secretive Practices in the Drug Supply Chain
Karen Van Nuys testified at the hearing, calling transparency “an essential first step.”
-
Ending Health Insurance for Generic Drugs Would Save Patients Money
Eliminating insurance for generics might make patients nervous at first, but the payoff would be stable and affordable prices.
Categorized in -
Prominent Health Executive Tom Priselac Named Vice Chair of Schaeffer Center Advisory Board
Priselac, who is CEO and president of Cedars-Sinai, has served on the board since its inception in 2011.
-
Should the Government Restrict Direct-to-Consumer Prescription Drug Advertising? Six Takeaways on their Effects.
Policymakers should proceed with caution as they design proposals to restrict advertising.
Categorized in -
Addressing Value Defects from Wasteful Services through Health Technology Assessment
All parts of the health care delivery system—ranging from biotechnologies to provider-led health care services—should be held equally accountable for providing valuable services to patients.
Categorized in -
Julie Zissimopoulos to Co-Chair 2023 NIA National Research Summit on Care, Services and Support for Persons Living with Dementia
The summit provides coordinated planning efforts that respond to the national plan to address Alzheimer’s Disease.
-
Schaeffer Co-Director Testifies on PBMs at Senate Congressional Hearing
Erin Trish was part of a panel of witnesses called to testify before the Committee on Commerce, Science and Transportation.